SCHEMBL21766068

SCHEMBL21766068

Cc1ccc(CNC(=O)C2CCN(S(=O)(=O)c3cc(Cl)cc(Cl)c3)CC2)cc1

nearest known ligand 0.85

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 2/20 0.85
TP53 P04637 1/20 0.72
EPHX2 P34913 2/20 0.69
ALDH1A1 P00352 5/20 0.68
PKM P14618 3/20 0.66
POLB P06746 2/20 0.66
PLA2G1B P04054 1/20 0.66
ATG4B Q9Y4P1 1/20 0.66
CYP3A4 P08684 2/20 0.65
TSHR P16473 1/20 0.65
MAPT P10636 1/20 0.64
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20258718 0.92 SLC13A5 (1.00) SLC13A5TP53EPHX2ALDH1A1PKM
SCHEMBL21766055 0.90 SLC13A5 (0.76) SLC13A5TP53EPHX2ALDH1A1PKM
SCHEMBL21765931 0.89 SLC13A5 (0.82) SLC13A5TP53EPHX2ALDH1A1POLB
SCHEMBL21766012 0.89 SLC13A5 (0.85) SLC13A5TP53EPHX2ALDH1A1POLB
SCHEMBL20258706 0.89 SLC13A5 (1.00) SLC13A5TP53ALDH1A1PKMPOLB
SCHEMBL21800690 0.89 SLC13A5 (0.85) SLC13A5TP53EPHX2ALDH1A1POLB
SCHEMBL21766050 0.88 SLC13A5 (0.76) SLC13A5TP53EPHX2ALDH1A1POLB
SCHEMBL20258662 0.86 SLC13A5 (0.80) SLC13A5TP53EPHX2ALDH1A1POLB
SCHEMBL21765924 0.85 SLC13A5 (0.65) SLC13A5TP53EPHX2ALDH1A1PKM
SCHEMBL21766052 0.84 SLC13A5 (0.77) SLC13A5EPHX2ALDH1A1POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-06 US disclosed
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE CS, GLS, GLS2 SLC13A5 261/4885TP53 3450/4885EPHX2 3210/4885
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate CS, GLS, GLS2 SLC13A5 261/4885TP53 3450/4885EPHX2 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.